Notably, a high risk of CRC or endometrial or ovarian cancer was observed for path_MLH1 (79.7% [72.7–85.9]) and path_MSH2 carriers (80.4% [72.2–87.5]) at 75 years of age and there was a 50% [39.1–62.9] lifetime risk for female path_MSH6 carriers (Supplementary Tables S3–S6). Here, MSH2 is linked to ovarian carcinoma.